Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STC 1010

Next Previous
Drug Profile

STC 1010

Alternative Names: STC-1010

Latest Information Update: 29 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Brenus Pharma
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Tumour cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Colorectal cancer
  • Preclinical Gastrointestinal cancer; Pancreatic cancer

Most Recent Events

  • 29 Jul 2025 Phase-I/II clinical trials in Colorectal cancer (Metastatic disease, Late-stage disease, Inoperable/Unresectable, First-line therapy) in France (Parenteral) (NCT06934538)
  • 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Colorectal cancer presented at 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 23 Apr 2025 Brenus Pharma plans the first-in-human phase Ia/II BreAK-CRC trial for Colorectal cancer (Metastatic disease, Late-stage disease, Inoperable/unresectable, First-line therapy) (Parenteral) in France in June 2025 (NCT06934538)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top